Abstract
Many antimycotic agents in a variety of formulations are available for treatment of vulvovaginal candidiasis. Nevertheless, numerous controversial issues remain concerning appropiate therapy for acute and chronic infections. Several complex issues have appeared in regard to treatment of women with human immunodeficiency virus infection and infection caused by non-albicans Candida species and resistant strains of Candida albicans.
| Original language | English |
|---|---|
| Pages (from-to) | 44-46 |
| Number of pages | 3 |
| Journal | Revista Iberoamericana de Micologia |
| Volume | 13 |
| Issue number | 2 |
| State | Published - 1 Jun 1996 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- HIV
- Non-albicans candida
- RVVC
- Treatment
- Vulvovaginal candidiasis
ASJC Scopus subject areas
- Microbiology
- Infectious Diseases
Fingerprint
Dive into the research topics of 'Update on treatment of vulvovaginal candidiasis'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver